We are passionate about developing innovative, ground-breaking tests, products and tools to enhance patient care, provide value to our clients, and transform information into knowledge and insights.
Click on a topic to see our innovations for each
We continuously strive to improve the service we deliver to our customers. That's why we implemented specimen tracking. By assigning unique bar codes and using handheld scanners, we can follow a patient specimen at every step of its journey to and through the laboratory.
We understand how challenging it can be to get through the daily to-do list. That's why we've created:
Colon cancer is the second leading cause of cancer deaths in the United States, but is often treatable when caught in early stages. Sixty percent of colon cancer deaths could be prevented if people were screened as indicated by guidelines, according to the U.S. Centers for Disease Control and Prevention. However, nearly one in three men and women age 50 and over have not been screened. Quest Diagnostics introduced ColoVantage®, a blood test that detects methylated DNA from the Septin 9 gene, a marker for colorectal cancer, that can help with detection of colorectal cancer in patients that have avoided established colorectal cancer screening tests such as colonoscopy, fecal occult blood tests, and fecal immunochemical tests (FITs). ColoVantage is not a replacement test for colonoscopy.
We develop innovative tests and products to assist physicians in diagnosing infectious diseases, and often provide the first diagnostic tests in the U.S. for emerging diseases, such as West Nile Virus, SARS, Lyme disease and Influenza A H1N1 (2009).
As a trusted provider of diagnostic testing, we're committed to delivering solutions for patients to securely manage their health. That's why we created Gazelle®, a mobile health app for smartphones that enables users to receive lab results and manage health information such as medications and emergency contacts. With Gazelle, users can see, store and share their vital health information with ease and security on the go.
Celera, a wholly owned subsidiary, was founded to sequence the human genome – the complete set of DNA and genes of an organism – and identify links between genetic variations and diseases. Its renowned discovery program has identified numerous genetic biomarkers that help assess disease risk or help physicians select appropriate therapies for many diseases.
Our AccuType® tests help predict a patient's response to certain drugs so that healthcare providers can select appropriate treatment for each patient's needs. Our AccuType® CP test is the first cardiovascular disease test to identify a patient's response to Plavix® (clopidogrel bisulfate). This anti-clotting drug is often prescribed to prevent heart attacks or strokes and is the second best-selling drug in the world. The AccuType® family also includes tests to help predict response related to warfarin, tamoxifin, therapies for hepatitis C virus, and others.
More than 50 million people in the U.S. have allergies. An essential step for providing the right treatment for these patients is to determine what is causing the allergy. The ImmunoCAP® test identifies hundreds of specific allergens with only a single blood sample. Among allergy blood tests ImmunoCAP is widely considered to be the most precise and reliable, with performance comparable to skin prick testing. However, unlike skin prick testing, ImmunoCAP does not require the patient to stop taking antihistamines or pose a risk of severe allergic reaction.
Timely decision making by physicians can be vital to patient outcomes. Simplexa(R) test kits on the 3M Integrated Cycler bring high-end PCR testing nearer patients, where timely decision making can impact patient outcomes. Simplexa molecular diagnostic test on the 3M(R) Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards, underscoring our commitment to developing industry-leading diagnostics that will improve patient care.
In April 2011, the Simplexa/3M technology also won a bronze 2011 Edison Award (Science & Medical category; Diagnostic Aids segment). The award is based on criteria that included technological innovation and marketplace success."
We know how frustrating it can be to receive test results that read "variables of unknown significance." The Athena Insight™ Variant Investigation Program gives you access to the information you need to clarify result significance. Our detailed service reports are easy to interpret and understand. Additionally, our team of genetic counselors and lab directors provides expert consultative services on each case, giving you deeper insight and answering technical questions. Our goal is to help you make more informed patient management decisions.
In 2009, the World Health Organization declared the first pandemic in over 40 years, recognizing the widespread H1N1 influenza virus. Focus Diagnostics®, our infectious disease business, was the first responder. Within about two weeks from the publication of the genetic code of H1N1, we developed a laboratory test and subsequently received emergency use authorization for Simplexa® Influenza A/H1N1. Early in 2010, this Simplexa test kit was the first to receive FDA approval, bringing reliable testing closer to at-risk patients in hospitals throughout the country. We were also the first commercial laboratory to develop a test for Tamiflu® resistance.
Fragile X is the leading cause of inherited mental retardation and the most common known single gene cause of autism. Physicians can use Xsense® to aid their identification of women who, as carriers, may be unaffected or slightly affected by Fragile X syndrome, but are at risk of passing it to offspring, regardless of the father's genetics. XSense employs a laboratory analysis technique that bypasses the need to perform the Southern Blot DNA analysis method in 99 percent of cases. Xsense is an accurate, faster testing option with results reported in about a week for the vast majority of patients.
With more than 1.1 billion patient encounters since 2000, we maintain the largest private clinical laboratory data repository in the U.S. Quest Diagnostics Health Trends™ reports identify and track disease and wellness benchmarks. They are made available as a public service to inform patients, healthcare professionals and policy makers about the current state of the nation's health. Our Health Trends™ reports include allergies, diabetes, heart health, H1N1 influenza A, kidney disease and more.
The 4myheart® Program, offered through our Berkeley HeartLab subsidiary, provides personalized care to help patients improve their cardiac health. A clinical educator addresses the patient's risk for heart disease and stroke, using the Berkeley HeartLab test results and a treatment plan from the patient's doctor. The 4myheart Program provides a personal touch through individual and group education, and many patients have seen impressive results in terms of cardiovascular risk reduction.
Ovarian cancer is the leading cause of death from gynecologic cancers in the U.S. and the fifth-leading cause of cancer deaths in women. Ovarian masses affect approximately one million women and lead to as many 300,000 ovarian mass surgeries in the U.S. each year. Quest Diagnostics is the only national lab to offer FDA-cleared OVA1™ test. The OVA1™ Test is a qualitative serum test that combines the results of five immunoassays into a single numerical result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The OVA1™ Test is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test is not intended as a screening or stand-alone diagnostic assay.
A negative OVA1™ Test result, in the setting of a positive pre-surgical assessment, should not preclude oncology referral. The OVA1™ Test is not indicated for patients with a diagnosis of malignancy within the last 5 years.
As an ONC-ATCB -certified solution*, Care360 EHR allows physicians to complete a wide range of patient-care-centered clinical tasks right at the point of care, including: